Galectin Therapeutics
GALT
78 hedge funds and large institutions have $28.8M invested in Galectin Therapeutics in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 10 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
1.12% more ownership
Funds ownership: 16.58% → 17.69% (+1.1%)
3% less funds holding
Funds holding: 80 → 78 (-2)
16% less capital invested
Capital invested by funds: $34.4M → $28.8M (-$5.66M)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
48% less call options, than puts
Call options by funds: $453K | Put options by funds: $865K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$995K |
| 2 |
State Street
Boston,
Massachusetts
|
+$400K |
| 3 |
Morgan Stanley
New York
|
+$299K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$257K |
| 5 |
VF
Virtu Financial
New York
|
+$190K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$149K |
| 2 |
WG
Winton Group
London,
United Kingdom
|
-$111K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$105K |
| 4 |
Jane Street
New York
|
-$88K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$60K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WG
76
Winton Group
London,
United Kingdom
| – | -$111K | -30,196 | Closed |
|
|
77
Jane Street
New York
| – | -$88K | -23,849 | Closed |
|
|
78
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$60K | -16,352 | Closed |
|
79
Wolverine Trading
Chicago,
Illinois
| – | -$39.9K | -11,471 | Closed |
|
80
Millennium Management
New York
| – | -$37K | -10,161 | Closed |
|
81
Victory Capital Management
San Antonio,
Texas
| – | -$30K | -8,067 | Closed |
|
|
TRCT
82
Tower Research Capital (TRC)
New York
| – | -$4K | -978 | Closed |
|
83
Group One Trading
Chicago,
Illinois
| – | -$2.76K | -794 | Closed |
|
GALT Hedge Fund Activity: Q4 2019 in Review
78 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2019, worth a combined $28.8M — down 16% from $34.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GALT and 8 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 25 added.
The largest buyer was BlackRock, adding an estimated $995K. The largest seller was Cambridge Investment Research Advisors, cutting an estimated $149K.
- 78 institutional investors held Galectin Therapeutics (GALT) as of Q4 2019, down from 80 in Q3 2019.
- Funds reported $28.8M of Galectin Therapeutics stock for Q4 2019, down 16% quarter-over-quarter.
- 8 funds opened new Galectin Therapeutics positions in Q4 2019 and 10 closed out, a net change of -2 holders.
- The largest Galectin Therapeutics buyer in Q4 2019 was BlackRock, an estimated $995K added.
- The largest Galectin Therapeutics seller in Q4 2019 was Cambridge Investment Research Advisors, an estimated $149K sold.
Based on aggregated 13F filings for Q4 2019.